Journal article
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Drug Safety, Vol.28(12), pp.1069-1074
2005
Abstract
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the contribution of specific antiretroviral drugs to the risk of these clinical endpoints, with evidence that lipoatrophy is strongly associated with the choice of nucleoside reverse transcriptase inhibitor therapy (specifically, stavudine and to a lesser extent zidovudine). The aetiological basis of metabolic complications of antiretroviral therapy has proven to be complex, in that the risk appears to be modulated by a number of lifestyle factors that have made the metabolic syndrome highly prevalent in the general population, with additional contributions from HIV disease status itself, as well as from individual drugs within the HIV protease inhibitor class. The currently licensed non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs, efavirenz and nevirapine, have been proven to have a favourable safety profile in terms of lipodystrophy complications. However, it must be noted that NNRTI drugs also have individual toxicity profiles that must be accounted for when considering and/or monitoring their use in the treatment of HIV infection.
Details
- Title
- Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
- Authors/Creators
- D. Nolan (Author/Creator)
- Publication Details
- Drug Safety, Vol.28(12), pp.1069-1074
- Publisher
- Adis International Ltd
- Identifiers
- 991005543996007891
- Copyright
- © 2005 Adis Data Information BV.
- Murdoch Affiliation
- Centre for Clinical Immunology and Biomedical Statistics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
611 File views/ downloads
79 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Citation topics
- 1 Clinical & Life Sciences
- 1.66 HIV
- 1.66.1372 HIV Comorbidities
- Web Of Science research areas
- Pharmacology & Pharmacy
- Public, Environmental & Occupational Health
- Toxicology
- ESI research areas
- Pharmacology & Toxicology